Qualifying for Wegovy (semaglutide 2.4 mg) comes down to a specific set of body mass index thresholds set by the FDA, and your doctor or insurer may layer additional requirements on top. The basic rule is straightforward: adults with a BMI of 30 or higher, or a BMI of 27 or higher paired with at least one weight-related health condition, meet the FDA-labeled criteria. But the gap between the FDA label and actually getting the medication into your hands can be surprisingly wide, shaped by insurance policies, prior authorization hurdles, and clinical screenings that vary from plan to plan.
The Core BMI Criteria
Wegovy’s FDA approval for chronic weight management in adults rests on two pathways. The first is a BMI at or above 30, which the medical community classifies as obesity. No additional diagnosis is needed. The second is a BMI between 27 and 29.9 (classified as overweight) combined with at least one weight-related comorbidity. Conditions that count include high blood pressure, type 2 diabetes, high cholesterol, and obstructive sleep apnea, among others. Your prescribing clinician will typically confirm your BMI through an in-office measurement and review your medical history for qualifying conditions.
One thing that trips people up: BMI is calculated from height and weight alone, and it does not distinguish between muscle mass and fat. If you are an unusually muscular person whose BMI technically hits 30 but who carries little excess body fat, a clinician may not consider you an appropriate candidate. Conversely, some people with a BMI just under 27 who carry significant visceral fat may still benefit, but they fall outside the labeled indication and would be considered off-label candidates, which most insurers will not cover.
The Cardiovascular Indication
In 2024, the FDA approved a second use for Wegovy that does not require the same BMI thresholds: reducing cardiovascular risk in adults with established heart disease who are overweight or obese but do not have diabetes.1BMJ. Wegovy: FDA approves weight loss drug to cut cardiovascular risk This expanded indication came after a large clinical trial showed that semaglutide lowered the risk of heart attacks and strokes in this population. If you have a history of cardiovascular events and a BMI of 27 or above, this pathway may allow you to qualify even if your primary reason for seeking the drug is heart health rather than weight loss per se. In practice, your cardiologist or primary care doctor would document the cardiovascular history to support the prescription.
How Adolescents Qualify
Wegovy is not limited to adults. In 2022, the FDA extended approval to patients aged 12 and older with a BMI at or above the 95th percentile for their age and sex. Adolescents with a BMI at or above the 85th percentile can also qualify if they have at least one obesity-related comorbidity.2PubMed Central. Semaglutide for Management of Obesity in Adolescents: Efficacy, Safety, and Considerations for Clinical Practice The approval was based on a 68-week trial that enrolled adolescents in exactly these BMI categories and found meaningful reductions in body weight compared to placebo.3PubMed Central. Once-Weekly Semaglutide in Adolescents with Obesity
For families exploring this option, the practical qualification process typically involves a pediatrician or pediatric endocrinologist confirming the BMI percentile using age- and sex-specific growth charts, documenting any comorbidities, and establishing that lifestyle changes alone have not been sufficient. Many pediatric specialists approach these prescriptions conservatively, and insurance coverage for adolescents can be even more difficult to secure than for adults.
What Insurance Plans Actually Require
Meeting the FDA criteria does not guarantee you will get the drug covered. Most commercial insurance plans impose their own layer of requirements through a process called prior authorization. Your doctor submits documentation proving you meet the plan’s specific criteria, and a reviewer at the insurance company decides whether to approve the prescription. This process can take days to weeks, and denials are common on the first attempt.
The details vary by plan, but common prior authorization requirements include:
- BMI documentation: A recorded BMI meeting the plan’s threshold, which usually mirrors the FDA label but occasionally sets a higher bar (some plans require a BMI of 30 or above for all applicants, effectively excluding the 27-to-29.9 comorbidity pathway).
- Failed lifestyle interventions: Evidence that you have tried diet and exercise programs, sometimes for a defined period such as three to six months, without achieving adequate weight loss.
- Prior medication trials: Some plans require that you first try and fail on a less expensive weight-loss medication before they will approve Wegovy.
- Specialist involvement: Certain insurers require that the prescription come from, or be co-managed by, a board-certified obesity medicine specialist or endocrinologist rather than a general practitioner.
If your initial prior authorization is denied, you have the right to appeal. Many denials are overturned on appeal when additional documentation is provided, particularly letters of medical necessity from your physician. It is worth asking your doctor’s office how experienced they are with Wegovy prior authorizations specifically, because offices that handle many of these requests tend to know what documentation each major insurer expects.
Staying On Wegovy After You Start
Getting your first prescription approved is only the beginning. Most commercial health plans also impose continuation criteria, meaning they periodically re-evaluate whether you should keep receiving the drug. A study of nine major U.S. commercial health plans found that all of them required documented weight loss for therapy continuation, typically at least four to five percent of baseline body weight within a set timeframe.4Center for the Evaluation of Value and Risk in Health. How US Commercial Health Plans Cover Wegovy for Weight Loss A couple of those plans went further, requiring that your BMI drop to 25 or below to maintain coverage.
This means that if you start Wegovy and do not lose enough weight within the insurer’s window, coverage can be pulled. Regular follow-up appointments where your weight is recorded become essential not just for health monitoring but for keeping your prescription funded. If your plan requires the four-to-five percent threshold, discuss realistic timelines with your prescriber. Some people respond more slowly to semaglutide, and a proactive letter from your doctor explaining gradual but genuine progress can sometimes satisfy a plan’s review even if the number is not quite at the threshold.
The Dose Titration Process
Wegovy is not a drug you start at full strength. Everyone who qualifies begins at a low dose of 0.25 mg once weekly, then increases in steps over about 16 to 20 weeks until reaching the target dose of 2.4 mg. The titration schedule exists to reduce gastrointestinal side effects like nausea, which are common and sometimes intense at higher doses. In practice, not everyone reaches the full 2.4 mg dose. Real-world data from an academic obesity clinic showed that while about 81 percent of semaglutide users escalated to at least 1 mg, only about 23 percent made it all the way to the 2.4 mg target.5PubMed Central. Real-world titration, persistence & weight loss of semaglutide and tirzepatide in an academic obesity clinic
Side effects during titration are the main reason people stop short of the full dose. If you tolerate a lower dose well and are losing weight, many clinicians will keep you there rather than push to 2.4 mg. This is a clinical judgment call, not an insurance issue. However, if your insurer’s continuation criteria require a certain rate of weight loss and you are on a lower dose, there is a tension point: you may need to either tolerate a higher dose or risk not meeting the plan’s threshold.
Lifestyle Requirements and What Your Doctor Should Screen For
Wegovy is labeled as an adjunct to a reduced-calorie diet and increased physical activity, not a standalone treatment. In practice, the degree to which clinicians enforce lifestyle components varies enormously. Some obesity medicine practices build in structured nutrition counseling, exercise programming, and behavioral health support. Others write the prescription with a general instruction to eat less and move more. A joint advisory from several major medical societies has pushed for more rigorous baseline screening before starting GLP-1 therapy, including assessment of dietary habits, emotional eating triggers, disordered eating patterns, muscle strength and body composition, and social determinants of health that might affect a patient’s ability to follow through on lifestyle changes.6PubMed Central. Nutritional priorities to support GLP-1 therapy for obesity
This matters for qualification in an indirect but important way. If your insurance plan requires documentation of failed lifestyle interventions, having a detailed record of what you actually tried, with specific programs, dates, and outcomes, strengthens your case considerably. A note in your chart saying “patient reports trying diet and exercise” is much weaker than records from a registered dietitian, a gym membership log, or participation in a structured weight management program.
Contraindications That Disqualify You
Even if you meet every BMI and insurance criterion, certain medical conditions will prevent a clinician from prescribing Wegovy. The drug carries a boxed warning related to thyroid C-cell tumors observed in animal studies, so anyone with a personal or family history of medullary thyroid carcinoma or a condition called Multiple Endocrine Neoplasia syndrome type 2 cannot use it. A history of pancreatitis is another red flag that most prescribers will take seriously, since GLP-1 receptor agonists as a class have been associated with rare but serious cases of pancreatitis and gallbladder disease.7PubMed Central. Glucagon-like peptide-1 receptor agonists: Evolution, gastrointestinal adverse effects, and future directions
Pregnancy and planned pregnancy are absolute contraindications. Wegovy should be stopped at least two months before a planned conception. If you are taking insulin or sulfonylureas for diabetes, your clinician will need to adjust those medications carefully because of the risk of dangerously low blood sugar when combined with semaglutide’s appetite-suppressing effects. And people with a history of severe depression or suicidal ideation should discuss this openly with their prescriber, as psychiatric side effects with GLP-1 drugs are an area of active surveillance.
Qualifying Through Telehealth
The rise of telehealth weight-loss clinics has made it easier for some people to qualify for Wegovy without visiting a doctor’s office. Companies like Ro, Hims, Found, and Calibrate offer remote evaluations where you provide your weight, height, and medical history, often verified through a video consultation with a licensed prescriber. A large retrospective study of patients prescribed semaglutide through a telehealth platform found an average body weight reduction of about 17 percent, with nausea and vomiting as the most common side effects, and no new safety concerns compared to traditional clinical settings.8PubMed Central. Real-World Evidence on Weight Loss and Safety With Semaglutide in Obesity Telehealth
The catch with telehealth is cost. Most of these platforms do not bill insurance directly for the medication. You pay out of pocket, sometimes at a significant discount through manufacturer savings programs, sometimes not. If you can get insurance coverage through your regular doctor, that is almost always the more affordable route. Telehealth platforms are most useful for people whose insurance will not cover Wegovy at all, who live in areas without nearby obesity medicine specialists, or who prefer the convenience and privacy of remote care. Some telehealth clinics have also prescribed compounded versions of semaglutide, which brings its own set of concerns.
Why Compounded Semaglutide Is Not the Same Thing
During periods of Wegovy shortage, compounding pharmacies have offered their own versions of semaglutide at lower prices. These compounded products are not FDA-approved and are not subject to the same manufacturing standards as the branded drug. A pharmacovigilance analysis of the FDA’s adverse event reporting system found that compounded GLP-1 products were associated with higher rates of abdominal pain, diarrhea, and nausea compared to manufactured versions. More concerning, the compounded products showed dramatically higher rates of preparation errors, contamination issues, and manufacturing problems. Hospitalization odds were roughly twice as high for people using compounded formulations.9PubMed. Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system
If you are considering a compounded version because you cannot get insurance coverage or afford the brand-name drug, it is worth understanding that you are accepting a different risk profile. These products are not interchangeable with Wegovy from a safety standpoint, even if the active ingredient is nominally the same. The FDA has issued multiple warnings about compounded semaglutide, and some states have moved to restrict or regulate compounding pharmacies more tightly in response.
What Happens If You Stop
Qualifying for Wegovy sets you on a path that, as current evidence suggests, does not have a clean off-ramp. When participants in the original STEP 1 trial stopped taking semaglutide after 68 weeks of treatment, they regained about two-thirds of the weight they had lost within the following year. The average participant had lost roughly 17 percent of their body weight on the drug but regained about 12 percentage points of that after stopping, leaving a net loss of only about 6 percent at the two-year mark. Cardiometabolic improvements in blood pressure, blood sugar, and cholesterol also drifted back toward where they started.10PubMed Central. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension
This has practical implications for how you think about qualification. Wegovy is not a short-term treatment that you take for six months to lose weight and then stop. It is, for most people, a long-term or indefinite commitment. Before you go through the process of qualifying and getting prior authorization, it is worth having a candid conversation with your doctor about the plan for the long term. Can you afford the copays or out-of-pocket costs indefinitely? Will your insurer continue to cover it year after year? What is the plan if coverage is dropped or the drug becomes unavailable? These are not hypothetical concerns. They are questions that determine whether qualifying for Wegovy actually translates into sustained benefit.
Wegovy Versus Other Semaglutide Products
Semaglutide is sold under multiple brand names at different doses for different conditions, and the distinction matters for qualification. Ozempic is semaglutide at lower doses (up to 2 mg) approved for type 2 diabetes management, not weight loss. Rybelsus is an oral semaglutide tablet, also approved for diabetes. Wegovy is the only semaglutide formulation with an FDA-approved indication specifically for chronic weight management. Using Ozempic off-label for weight loss is something some doctors do, but insurance plans generally will not cover an off-label use, and one analysis of Medicaid data found that coverage changes for obesity medications had essentially no effect on GLP-1 prescribing for diabetes indications, suggesting that off-label use of diabetes formulations for weight loss is not very common in that program.11NBER. Medicaid Coverage for Obesity Medications: Utilization and Net-of-Rebate Spending
If your doctor has been prescribing Ozempic for weight loss and you want to transition to the properly indicated product, the qualification process for Wegovy starts fresh with your insurer. The good news is that documented weight loss on Ozempic can sometimes serve as evidence that semaglutide works for you, which strengthens a prior authorization request. The bad news is that some plans treat the switch as a new start and require you to meet all initial criteria from scratch, including documentation of failed lifestyle interventions.
Newer Alternatives on the Horizon
Wegovy is not the only game in town, and competition may affect how easily you can qualify in the future. Tirzepatide, sold as Zepbound for weight loss, works on two gut hormone receptors rather than one and has shown weight reductions in clinical trials that sometimes exceed what semaglutide achieves. Across the broader class of approved obesity pharmacotherapies, weight reductions range from roughly 8 to 21 percent of body weight depending on the drug and the patient population.12PubMed Central. Statutory regulation of obesity pharmacotherapy: analysis of domestic and international approaches As more options become available, insurers may start adjusting their coverage policies, potentially requiring patients to try one drug before being approved for another. It is also possible that increased competition drives prices down, which could make qualification less of an obstacle simply because the financial stakes for insurers shrink. For now, though, qualification for each branded product follows its own FDA label and its own insurer gauntlet.